Effects of aluminum sulfate on delta-aminolevulinate dehydratase from kidney, brain, and liver of adult mice


Departamento de Química, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, RS, Brasil

Abstract

The purpose of the present study was to investigate the \textit{in vitro} and \textit{in vivo} effects of aluminum sulfate on delta-aminolevulinic acid dehydratase (ALA-D) activity from the brain, liver and kidney of adult mice (Swiss albine). \textit{In vitro} experiments showed that the aluminum sulfate concentration needed to inhibit the enzyme activity was 1.0-5.0 mM (N = 3) in brain, 4.0-5.0 mM (N = 3) in liver and 0.0-5.0 mM (N = 3) in kidney. The \textit{in vivo} experiments were performed on three groups for one month: 1) control animals (N = 8); 2) animals treated with 1 g\% (34 mM) sodium citrate (N = 8) and 3) animals treated with 1 g\% (34 mM) sodium citrate plus 3.3 g\% (49.5 mM) aluminum sulfate (N = 8). Exposure to aluminum sulfate in drinking water inhibited ALA-D activity in kidney (23.3 – 3.7\%, mean – SEM, P<0.05 compared to control), but enhanced it in liver (31.2 – 15.0\%, mean – SEM, P<0.05). The concentrations of aluminum in the brain, liver and kidney of adult mice were determined by graphite furnace atomic absorption spectrometry. The aluminum concentrations increased significantly in the liver (527 – 3.9\%, mean – SEM, P<0.05 compared to control), but enhanced it in liver (527 – 3.9\%, mean – SEM, P<0.05). The concentrations of aluminum in the brain, liver and kidney of adult mice were determined by graphite furnace atomic absorption spectrometry. The aluminum concentrations increased significantly in the liver (527 – 3.9\%, mean – SEM, P<0.05) and kidney (283 – 1.7\%, mean – SEM, P<0.05 but did not change in the brain of aluminum-exposed mice. One of the most important and striking observations was the increase in hepatic aluminum concentration in the mice treated only with 1 g\% sodium citrate (34 mM) (217 – 1.5\%, mean – SEM, P<0.05 compared to control). These results show that aluminum interferes with delta-aminolevulinate dehydratase activity \textit{in vitro} and \textit{in vivo}. The accumulation of this element was in the order: liver > kidney > brain. Furthermore, aluminum had only inhibitory properties \textit{in vitro}, while \textit{in vivo} it inhibited or stimulated the enzyme depending on the organ studied.

Key words
- Aluminum sulfate
- Aluminum determination
- Delta-aminolevulinate dehydratase

Introduction

Aluminum was thought to be nontoxic in the past. However, recent data have raised serious questions about the hazards of this metal (1,2). Aluminum salts administered by different routes can produce toxic effects in animal models (3-5) some of which involve alterations in enzymatic activities (6,7). It is presently accepted that aluminum intoxication may induce anemia and encephalopathy in humans and animals (8). Touam and
colleagues (9) and Kaiser and Schwartz (3) proposed that aluminum may cause microcytic anemia by a direct effect on heme biosynthesis, specifically alterations in the activity of delta-aminolevulinic acid dehydratase (ALA-D, E.C. 4.2.1.24). ALA-D is a sulfhydryl-containing enzyme that is inhibited by heavy metals and sulfhydryl reagents (10-16) and seems to be the principal lead-binding protein in human erythrocytes (17). The toxic effects of aluminum on ALA-D may involve protein synthesis, enzyme inhibition or enzyme activation (18).

ALA-D inactivation may lead to an accumulation of delta-aminolevulinic acid (substrate) that can cause an overproduction of reactive oxygen species which, in turn, could explain the toxic effects of metals (19,20). In view of the pro-oxidant effect of ALA, a study of the inhibition of ALA-D by aluminum can contribute to a better understanding of the toxicology of this metal. These processes may contribute to oxidative stress in cells and may be related to degenerative cellular mechanisms.

The main purpose of the present study was to investigate the in vitro and in vivo effects of aluminum sulfate on delta-aminolevulinic acid dehydratase in the brain, liver and kidney and the aluminum deposition in these organs of adult mice.

Material and Methods

Animals

Mice of both sexes weighing 25-30 g from our breeding colony were used. The animals were maintained in an air-conditioned room (22-25°C) under natural lighting conditions and housed eight to a cage.

Material

Delta-aminolevulinic acid (ALA), albumin and Coomassie blue were purchased from Sigma Chemical Co. (St. Louis, MO, USA), and nitric acid from Merck (Darmstadt, Germany). All other chemicals used in this study were of the highest purity available.

Treatment

The in vivo experiments were performed over a period of one month with the substances supplied in the drinking water (ad libitum). The animals were divided into three groups: 1) control animals; 2) animals treated with 1 g% (34 mM) sodium citrate, and 3) animals treated with 1 g% (34 mM) sodium citrate plus 3.3 g% (49.5 mM) aluminum sulfate. These concentrations were used according to previous results obtained in our laboratory (data not shown). Sodium citrate was added because complex formation between Al³⁺ and dietary citrate may facilitate absorption or tissue retention, or both (21). Food and water intake was measured daily. The treatment did not affect food or water intake by the animals. All solutions were administered from plastic bottles.

Contamination control

To avoid metal contamination, only plastic material was used. All material (pipette tips, volumetric flasks) was left at least 48 h in a 1:9 HNO₃/ethanol mixture (v/v) and washed with Milli-Q water shortly before use (22). Animal decapitation and manipulation and sample and reagent preparations were carried out on a class Trox clean bench class 100.

Sample preparation and biochemical assay

Mice were anesthetized with ether and killed by decapitation. Liver, brain and kidney were rapidly dissected and immediately placed on ice. Liver was homogenized in 7 volumes, kidney in 5 volumes and brain in 2 volumes of 150 mM NaCl with ten up-and-down strokes at approximately 1200 rev/min
in a Teflon-glass homogenizer. The homogenate was centrifuged at 4000 g at 4°C for 10 min to yield a low-speed supernatant fraction that was used for enzyme assay.

For the *in vitro* assays, aluminum sulfate stock solution (50 mM) was prepared in deionized water, stored in plastic containers and used for a period of two weeks. The dilute solutions were prepared fresh daily.

ALA-D activity was assayed according to the method of Sassa (23) by measuring the rate of porphobilinogen formation, except that the incubation medium for the aluminum sulfate assays contained 45 mM sodium phosphate buffer, pH 5.5. Phosphate buffer was used in these experiments because suitable enzyme activity was not obtained when citrate buffer was used (data not shown). The pH of the incubation medium was 5.5 to avoid problems with aluminum hydrolysis and precipitation as Al(OH)₃ (24). In all enzyme assays, the final concentration of ALA was 2.2 mM. The product of reaction was determined with modified Ehrlich reagent at 555 nm using a molar absorption coefficient of 6.1 x 10⁴ M⁻¹ cm⁻¹ (23) for the Ehrlich-porphobilinogen salt. Incubation was started by adding 150 µl of the tissue preparation. The final volume of the incubation medium was 250 µl. Protein concentration was measured by the method of Bradford (25).

**Aluminum determination**

To measure the aluminum content in the samples, a 1000 mg/l aluminum stock solution was prepared from aluminum nitrate (Merck) in water and standard solutions were prepared by appropriate dilution of the aluminum stock solution. Nitric acid was further purified by sub-boiling distillation. Water was distilled, deionized and further purified with a Millipore system. Samples were placed in previously weighed flasks and 2.5 ml nitric acid was added for brain and kidney or 5.0 ml for liver digestion and aluminum solubilization. The flasks were tightly closed and maintained at room temperature for 72 h for complete sample digestion. The samples were diluted with water (1:1). The aluminum concentration was measured with a Varian SpectraAA atomic absorption spectrometer with a deuterium background corrector, a Varian GTA-100 graphite furnace and an auto sampler. Analyses were performed using pyrolytic graphite-coated tubes with L’yov platforms. The hollow cathode lamp was used at 10 mA at the 309.3 nm resonance line, the spectral slit width was set at 0.7 nm, and the injection volume used was 5 µl. The pyrolysis and atomization temperature used were 1000 and 2500°C, respectively; the absorbance signal was measured in the peak area and the purging gas used was argon, with stop flow at the time of atomization. A Trox clean bench class 100 and a Berghof BSP 929 sub-boiling distillation apparatus were used.

**Statistical analysis**

Data were analyzed by one-way analysis of variance followed by the Duncan test when the F test was significant (P<0.05) to determine the differences between the control and the other groups.

**Results**

**In vitro effect of aluminum sulfate on ALA-D activity**

ALA-D activity was measured in brain, liver and kidney homogenates of adult mice using increasing aluminum sulfate concentrations in the incubation medium (Table 1). Cerebral ALA-D activity decreased with 0.5 to 5.0 mM of aluminum sulfate (P<0.05). ALA-D from liver was significantly inhibited by 4.0 and 5.0 mM aluminum sulfate (P<0.05) and renal activity was inhibited by 1.0 to 5.0 mM (P<0.05) compared to the control group.
In vivo effect of aluminum sulfate on ALA-D activity

In vivo treatment with aluminum sulfate did not inhibit ALA-D activity in the brain homogenate (Table 2). In liver, treatment with citrate and aluminum plus citrate increased ALA-D activity by 30-40% when compared to the control group. In kidney, ALA-D activity was inhibited 24% in the aluminum plus citrate group when compared to the control group. There was no difference between the control and citrate groups.

Aluminum measurement by graphite furnace atomic absorption spectrometry

The distribution of aluminum in the organs is summarized in Table 3. Treatment did not increase aluminum concentration in brain. In liver, citrate and citrate plus aluminum caused an increase in aluminum concentration when compared to the control group, with a difference in aluminum concentration between these two groups. Finally, in kidney aluminum concentration was increased in the aluminum plus citrate group when compared to the control and citrate groups.

Discussion

This study shows that aluminum sulfate interferes with ALA-D activity in brain, liver and kidney of adult mice. There are several hypotheses for ALA-D inhibition by aluminum, one of them described by Zaman and colleagues (26), who proposed that aluminum inhibits ALA-D by attaching to the -SH group of the active site of the enzyme, thus reducing its activity. However, aluminum has low affinity for -SH groups which makes a direct effect of aluminum on cysteinyl residues of ALA-D unlikely. Nevertheless, inhibition of ALA-D activity can contribute to increasing ALA accumulation which in turn can enhance generation of free radicals, aggravating oxidative damage to

Table 1 - In vitro effect of aluminum sulfate on delta-aminolevulinic acid dehydratase (ALA-D) from brain, liver and kidney of adult mice.

Data are reported as mean ± SEM for at least three experiments. *P<0.05 compared to control (Duncan test). ALA-D activity is reported as percent of control activity (0 mM aluminum sulfate). The control enzyme activities were 38 ± 1.0 in brain, 238 ± 13 in liver and 74 ± 6 in kidney, reported as nmol porphobilinogen h⁻¹ mg protein⁻¹.

<table>
<thead>
<tr>
<th>Aluminum (mM)</th>
<th>Brain</th>
<th>Liver</th>
<th>Kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>0.5</td>
<td>89 ± 4.3*</td>
<td>87 ± 12.1</td>
<td>95 ± 3.7</td>
</tr>
<tr>
<td>1.0</td>
<td>86 ± 3.0*</td>
<td>90 ± 6.0</td>
<td>80 ± 2.7*</td>
</tr>
<tr>
<td>2.5</td>
<td>80 ± 1.7*</td>
<td>92 ± 15.6</td>
<td>78 ± 2.7*</td>
</tr>
<tr>
<td>4.0</td>
<td>65 ± 6.5*</td>
<td>50 ± 3.8*</td>
<td>37 ± 9.0*</td>
</tr>
<tr>
<td>5.0</td>
<td>15 ± 2.9*</td>
<td>12 ± 1.2*</td>
<td>14 ± 1.8*</td>
</tr>
</tbody>
</table>

Table 2 - In vivo effect of aluminum sulfate on delta-aminolevulinic acid dehydratase (ALA-D) from brain, liver and kidney of adult mice.

Data are reported as mean ± SEM for at least five animals per group. *P<0.05 compared to control (Duncan test). ALA-D activity is reported as percent of control. The control enzyme activities were 32 ± 2.7 in brain, 211 ± 26 in liver, and 88 ± 14 in kidney, reported as nmol porphobilinogen h⁻¹ mg protein⁻¹.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control</th>
<th>Citrate</th>
<th>Citrate + aluminum sulfate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>100</td>
<td>90.2 ± 6.0</td>
<td>93.5 ± 6.5</td>
</tr>
<tr>
<td>Liver</td>
<td>100</td>
<td>148.3 ± 19.0*</td>
<td>131.2 ± 15.0*</td>
</tr>
<tr>
<td>Kidney</td>
<td>100</td>
<td>86.2 ± 13.0</td>
<td>76.7 ± 3.7</td>
</tr>
</tbody>
</table>

Table 3 - Tissue aluminum concentration determined by graphite furnace atomic absorption spectrometry (GFAAS).

Data are reported as µg/g wet weight. *P<0.05 compared to control (Duncan test); **P<0.05 compared to control and to the citrate group (Duncan test). Each result represents the mean for six animals and two determinations by GFAAS.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control</th>
<th>Citrate</th>
<th>Citrate + aluminum sulfate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>0.321 ± 0.021</td>
<td>0.291 ± 0.013</td>
<td>0.320 ± 0.031</td>
</tr>
<tr>
<td>Liver</td>
<td>0.639 ± 0.054</td>
<td>1.386 ± 0.011*</td>
<td>3.368 ± 0.037**</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.592 ± 0.052</td>
<td>0.502 ± 0.027</td>
<td>1.679 ± 0.010**</td>
</tr>
</tbody>
</table>
cell components (27). Thus, all these events can contribute to promoting aluminum toxicity in our treatment.

Aluminum sulfate inhibited brain ALA-D activity in vitro but not in vivo (Tables 1 and 2), possibly because in our intoxication model aluminum did not accumulate in brain after in vivo exposure (Table 3). Our results agree with those reported by Garbossa and colleagues (28) who stated that prolonged treatment (15 weeks) with a high aluminum citrate concentration (100 mmol/l) did not result in a significant increase in brain aluminum content.

In vitro inhibition of the hepatic enzyme was observed only at high aluminum concentrations (higher than 4.0 mM). Based on the inhibitory effect of a high dose of aluminum it would be more reasonable to expect an inhibition of hepatic ALA-D after in vivo exposure. However, hepatic ALA-D activity of mice exposed to aluminum in drinking water was increased about 30-40% when compared to control groups. In addition, the activation caused by aluminum was probably related to an increase in aluminum concentration in this organ (Table 3).

The greater deposition of aluminum in liver observed in the present study is in accordance with the findings of Fiejka and colleagues (5) which showed that the liver is the main target organ for aluminum accumulation and toxicity. Presumably, the activation of hepatic ALA-D can be regarded as a manifestation of aluminum toxicity or as part of an adaptive hepatic response to aluminum accumulation.

It is interesting that citrate alone increased about 2-fold while citrate plus aluminum increased about 5-fold the accumulation of aluminum in liver (Table 3) even though the level of aluminum contamination in tap water used in the present study (25 ppb, or approximately 1 µM; data not shown) was about 5 orders of magnitude lower than the high (49.5 mM) toxicologic level of aluminum in water administered to the aluminum plus citrate group. The increase in the hepatic levels of aluminum in animals drinking tap water supplemented with 1 g% sodium citrate may be of toxicologic importance, since the human population consumes food and beverages containing citrate and drink water that contains aluminum in ranges similar to that observed in the present study (10).

In the kidney, aluminum inhibited ALA-D after in vitro and in vivo treatment and the aluminum concentration was increased after in vivo exposure (Table 3). It is noteworthy that the levels of aluminum in kidney of exposed mice were considerably lower (60 µM) than the concentration required to inhibit the renal enzyme in vitro (1.0 mM). Consequently, the inhibition of the renal enzyme after in vivo exposure cannot be solely explained by aluminum accumulation in this organ. The inhibition of renal ALA-D by aluminum contrasts with the activation observed in liver. The opposite effect of aluminum on renal and hepatic ALA-D after in vivo exposure can be explained in terms of some protecting tissue-specific factor present in liver, but not in kidney. This consideration is supported in part by the in vitro results which showed that the renal enzyme tended to be more sensitive to the inhibitory effects of aluminum.

The inhibition of ALA-D may cause an increase in 5-aminolevulinic acid concentration that presumably enhances the production of free radicals in affected tissues (19,20). Hepatic aluminum toxicity in our intoxication model possibly had no direct relationship with aminolevulinic acid accumulation because hepatic ALA-D was activated after exposure to aluminum (Tables 2 and 3). Alternatively, aluminum could interfere with iron disposition, making this metal more available to catalyze free radical production in liver (29). In contrast to liver, 5-aminolevulinic acid accumulation presumably plays a role in aluminum toxicity in the kidney because renal ALA-D is inhibited after aluminum exposure (Tables 2 and 3).
An important observation of the present study was that citrate increases the aluminum deposition in the liver of mice. These findings are of considerable importance since a similar phenomenon could occur in humans who consume citrate daily in the diet and are exposed to low levels of aluminum which are judged safe from a toxicologic point of view but may become toxic in the presence of citrate.

References